Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

Inclusion Criteria:

• Men and women age 18-65;

• Current DSM-IV BDD or its delusional variant (delusional disorder, somatic type) forat least 3 months;

• A minimum total score of 20 on the Yale-Brown Obsessive Compulsive Scale Modified forBDD (BDD-YBOCS) (19);

• Suitable for treatment in an outpatient setting

Exclusion Criteria:

• Unstable medical illness, including renal failure or dialysis;

• Myocardial infarction within 6 months;

• Current pregnancy or lactation, or inadequate contraception in women of childbearingpotential;

• A need for prn benzodiazepines, another antiepileptic medication, or an anticipatedchange in the dose of any concomitant medications while receiving treatment withlevetiracetam;

• Clinically significant suicidality, including a suicide attempt within the past twomonths;

• Lifetime history of DSM-IV dementia, schizophrenia, or any other DSM-IV psychoticdisorder that is not attributable to BDD;

• Current or recent (past 3 months) DSM-IV substance abuse or dependence;

• Initiation of ongoing psychotherapy from a mental health professional within 3 monthsprior to study baseline;

• Ongoing cognitive-behavioral therapy from a mental health professional;

• Previous treatment with levetiracetam;

• Treatment with investigational medication, depot neuroleptics, or ECT within the past 3 months.